Singer, new broker note out..10 Jul 2023 11:49
Totally is one of the only UK-quoted providers of independent healthcare services that has the scale and breadth to help address this and has been growing rapidly in recent years. Whilst procurement delays and inflationary pressures have impacted in the short term, the recent pullback in the shares looks overdone and has, in our opinion, created a compelling buying opportunity.
Medium term, we see scope for a re-rating as further growth is delivered and as margins continue to improve on scale and improved mix. We initiate with a Buy recommendation.
We believe we have pitched our forecasts conservatively to reflect short term inflationary pressures and contract transitions. Despite this, we expect margins to continue to improve on scale efficiencies and improved mix. We expect strong cash generation to resume this year and earnings growth in FY25 (EPS +40%), with scope for upside to these forecasts on further contract win momentum and potentially accretive future M&A.
Compelling value on offer Following the recent pullback, TLY trades on just 4.9x FY24 EV/EBITDA, falling to 3.9x in FY25. This is a significant discount to its peers (on 8-10x), its historical averages and to comparable transactions in the space. Furthermore, the model is asset-light and highly cash generative, offering a 10% FCF yield in FY25 and a 3% dividend yield. We initiate coverage with a Buy recommendation and 12m Target Price of 30p.